Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy for HBeAg Positive Chronic Hepatitis B
NCT00291616Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2005
- Primary completion
- Aug 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of thymosin alpha 1 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Seoul National University Hospital. Primary endpoints: Hepatitis B e Antigen Seroconversion at 96 weeks and Hepatitis B Virus DNA Titer Less Than 20,000 IU/mL at 96 weeks. Started Dec 2005; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00291616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291616.